• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转录组学在长期治疗的 HIV 感染中的年龄加速。

Transcriptomics age acceleration in prolonged treated HIV infection.

机构信息

The Systems Virology Lab, Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

出版信息

Aging Cell. 2023 Oct;22(10):e13951. doi: 10.1111/acel.13951. Epub 2023 Aug 7.

DOI:10.1111/acel.13951
PMID:37548368
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10577541/
Abstract

Biological aging in people with HIV (PWH) with prolonged successful antiretroviral therapy (ART) is convoluted and poorly defined. Here, we aimed to investigate the transcriptomics age estimator (TAE) in a cohort of 178 PWH on prolonged successful ART with immune reconstitution and viral suppression from the Copenhagen Comorbidity (COCOMO) cohort. We also used 143 clinical, demographical, and lifestyle factors to identify the confounders potentially responsible or associated with age acceleration. Among the PWH, 43% had an accelerated aging process (AAP), and 21% had decelerated aging process (DAP). DAP is linked with older age, European ancestry, and higher use of tenofovir disoproxil/alafenamide fumarate. A directionally class-based gene set enrichment analysis identified the upregulation of inflammatory pathways (e.g., cytokine and Retinoic acid-inducible gene I (RIG-I)-like receptor signaling pathways) and immune response like T-cell receptor signaling, antigen processing, and presentation in AAP and the downregulation of metabolic processes like oxidative phosphorylation, pyruvate metabolism.

摘要

在接受长期成功抗逆转录病毒治疗(ART)的 HIV 感染者(PWH)中,生物衰老较为复杂且定义不明确。在此,我们旨在通过哥本哈根合并症(COCOMO)队列中 178 名接受长期成功 ART 治疗且免疫重建和病毒抑制的 PWH 队列,研究转录组学年龄估算器(TAE)。我们还使用了 143 项临床、人口统计学和生活方式因素,以确定可能导致或与加速衰老相关的混杂因素。在 PWH 中,43%存在加速衰老过程(AAP),21%存在减速衰老过程(DAP)。DAP 与年龄较大、欧洲血统和更常使用替诺福韦二吡呋酯/丙酚替诺福韦有关。基于方向的基因集富集分析发现,AAP 中炎症途径(如细胞因子和 RIG-I 样受体信号通路)和免疫反应(如 T 细胞受体信号、抗原处理和呈递)上调,而代谢过程(如氧化磷酸化、丙酮酸代谢)下调。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a370/10577541/624b293606d8/ACEL-22-e13951-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a370/10577541/624b293606d8/ACEL-22-e13951-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a370/10577541/624b293606d8/ACEL-22-e13951-g002.jpg

相似文献

1
Transcriptomics age acceleration in prolonged treated HIV infection.转录组学在长期治疗的 HIV 感染中的年龄加速。
Aging Cell. 2023 Oct;22(10):e13951. doi: 10.1111/acel.13951. Epub 2023 Aug 7.
2
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.从依非韦伦、恩曲他滨和富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺与利匹韦林和恩曲他滨联合复方制剂用于治疗 HIV-1 感染病毒抑制成人:一项随机、双盲、多中心、3b 期、非劣效性研究。
Lancet HIV. 2017 May;4(5):e205-e213. doi: 10.1016/S2352-3018(17)30032-2. Epub 2017 Mar 2.
3
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺与利匹韦林和恩曲他滨固定剂量复方制剂用于病毒学抑制的 HIV-1 感染成人:一项随机、双盲、多中心、3b 期、非劣效性研究。
Lancet HIV. 2017 May;4(5):e195-e204. doi: 10.1016/S2352-3018(17)30031-0. Epub 2017 Mar 2.
4
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.在病毒学抑制的成人中,以恩曲他滨为骨架的固定剂量组合形式给予替诺福韦艾拉酚胺与替诺福韦酯治疗HIV-1感染的疗效和安全性:一项随机、双盲、活性对照3期试验。
Lancet HIV. 2016 Apr;3(4):e158-65. doi: 10.1016/S2352-3018(16)00024-2. Epub 2016 Mar 14.
5
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.恩曲他滨和丙酚替诺福韦艾拉酚胺与恩曲他滨和替诺福韦二吡呋酯用于 HIV-1 暴露前预防的长期安全性和有效性:一项随机、双盲、安慰剂对照、3 期临床试验的第 96 周结果。
Lancet HIV. 2021 Jul;8(7):e397-e407. doi: 10.1016/S2352-3018(21)00071-0.
6
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.多替拉韦加拉米夫定与恩曲他滨和丙酚替诺福韦艾拉酚胺或富马酸替诺福韦二吡呋酯对比依非韦伦、恩曲他滨和富马酸替诺福韦二吡呋酯,用于治疗人类免疫缺陷病毒 1 型感染的初始治疗(ADVANCE):一项随机、3 期、非劣效性试验的第 96 周结果。
Lancet HIV. 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1.
7
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.一项多中心、开放标签、3b 期、随机试验:在 HIV-1 病毒学抑制的 60 岁及以上人群中,将包含富马酸替诺福韦二吡呋酯的方案转换为艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺单片复方制剂方案时,对骨矿物质密度的影响。
Lancet HIV. 2019 Oct;6(10):e655-e666. doi: 10.1016/S2352-3018(19)30195-X.
8
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺在 HIV-1 感染的病毒学抑制成人中的抗逆转录病毒治疗方案:一项随机、活性对照、多中心、开放性标签、3 期、非劣效性研究。
Lancet Infect Dis. 2016 Jan;16(1):43-52. doi: 10.1016/S1473-3099(15)00348-5. Epub 2015 Nov 2.
9
Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection.从包含阿巴卡韦/拉米夫定或恩曲他滨/替诺福韦酯的方案转换为恩曲他滨/丙酚替诺福韦酯不会影响中枢神经系统 HIV-1 感染。
Infect Dis (Lond). 2019 Nov-Dec;51(11-12):838-846. doi: 10.1080/23744235.2019.1670352. Epub 2019 Sep 26.
10
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.初治抗逆转录病毒治疗患者中逆转录酶和蛋白酶常见的HIV-1传播耐药突变以及对含富马酸替诺福韦二吡呋酯或替诺福韦艾拉酚胺方案的反应
J Infect Dis. 2017 Mar 15;215(6):920-927. doi: 10.1093/infdis/jix015.

引用本文的文献

1
The energy-health-environment nexus: assessing the transboundary impacts of coal-fired power plants.能源-健康-环境关联:评估燃煤发电厂的跨界影响。
Front Public Health. 2025 Jul 31;13:1581460. doi: 10.3389/fpubh.2025.1581460. eCollection 2025.
2
Emerging Roles of m7G-Cap Hypermethylation and Nuclear Cap-Binding Proteins in Bypassing Suppression of eIF4E-Dependent Translation.m7G帽超甲基化和核帽结合蛋白在绕过eIF4E依赖性翻译抑制中的新作用
Viruses. 2025 Mar 5;17(3):372. doi: 10.3390/v17030372.
3
GNLY+CD8+ T cells bridge premature aging and persistent inflammation in people living with HIV.

本文引用的文献

1
Network-based multi-omics integration reveals metabolic at-risk profile within treated HIV-infection.基于网络的多组学整合揭示了治疗后 HIV 感染中的代谢风险特征。
Elife. 2023 Feb 16;12:e82785. doi: 10.7554/eLife.82785.
2
Biological Aging in People Living with HIV on Successful Antiretroviral Therapy: Do They Age Faster?成功接受抗逆转录病毒疗法的 HIV 感染者的生物学衰老:他们衰老得更快吗?
Curr HIV/AIDS Rep. 2023 Apr;20(2):42-50. doi: 10.1007/s11904-023-00646-0. Epub 2023 Jan 25.
3
A matched cohort study investigating premature, accentuated, and accelerated aging in people living with HIV.
颗粒溶素阳性(GNLY+)的CD8+ T细胞在HIV感染者中连接了过早衰老和持续性炎症。
Emerg Microbes Infect. 2025 Dec;14(1):2466695. doi: 10.1080/22221751.2025.2466695. Epub 2025 Mar 26.
4
Oxidative phosphorylation in HIV-1 infection: impacts on cellular metabolism and immune function.HIV-1 感染中的氧化磷酸化:对细胞代谢和免疫功能的影响。
Front Immunol. 2024 Mar 11;15:1360342. doi: 10.3389/fimmu.2024.1360342. eCollection 2024.
一项匹配队列研究调查了 HIV 感染者的过早、加重和加速衰老。
HIV Med. 2023 May;24(5):640-647. doi: 10.1111/hiv.13375. Epub 2022 Aug 7.
4
Accelerated aging with HIV begins at the time of initial HIV infection.感染HIV后加速衰老始于初次感染HIV之时。
iScience. 2022 Jun 30;25(7):104488. doi: 10.1016/j.isci.2022.104488. eCollection 2022 Jul 15.
5
Modeling transcriptomic age using knowledge-primed artificial neural networks.使用知识引导的人工神经网络对转录组年龄进行建模。
NPJ Aging Mech Dis. 2021 Jun 1;7(1):15. doi: 10.1038/s41514-021-00068-5.
6
Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial.抗逆转录病毒治疗开始后 2 年,HIV 感染者的表观遗传年龄加速变化:NEAT001/ANRS143 随机试验的子研究。
Lancet HIV. 2021 Apr;8(4):e197-e205. doi: 10.1016/S2352-3018(21)00006-0.
7
BiT age: A transcriptome-based aging clock near the theoretical limit of accuracy.BiT 年龄:基于转录组的接近理论精度极限的衰老时钟。
Aging Cell. 2021 Mar;20(3):e13320. doi: 10.1111/acel.13320. Epub 2021 Mar 3.
8
Modeling the human aging transcriptome across tissues, health status, and sex.跨组织、健康状况和性别的人类衰老转录组建模。
Aging Cell. 2021 Jan;20(1):e13280. doi: 10.1111/acel.13280. Epub 2020 Dec 18.
9
RNAAgeCalc: A multi-tissue transcriptional age calculator.RNAAgeCalc:一种多组织转录组年龄计算器。
PLoS One. 2020 Aug 4;15(8):e0237006. doi: 10.1371/journal.pone.0237006. eCollection 2020.
10
Do people living with HIV experience greater age advancement than their HIV-negative counterparts?HIV 感染者的衰老速度是否比 HIV 阴性者更快?
AIDS. 2019 Feb 1;33(2):259-268. doi: 10.1097/QAD.0000000000002063.